The DEA is no longer banning these drugs

This study could be a game changer

First Phase 3 trial receives government funding

2 years til medical legalization!

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Creso Pharma’s wholly-owned psychedelics subsidiary,
Halucenex Life Sciences Inc. making progress ahead of
its planned Phase II clinical trials

Red Light Holland and Mistercap LLC Partnership Update

George Tziras to succeed Peter Rands as Small Pharma Chief Executive Officer

Awakn Provides a Business & Corporate Update

Small Pharma Reports Fiscal First Quarter 2023 Highlights

Zylorion Announces Filing of U.S. Provisional Patent For Novel Second-Generation Psilocybin-Based Compound

Doseology Expands into US Retail Market

Enveric Biosciences Announces Reverse Stock Split

Greenbrook TMS Announces Closing of Success TMS Acquisition and US$75 Million Credit Facility With Madryn Asset Management

Numinus Wellness Inc. Reports Q3 2022 Results

Pasithea Therapeutics Awarded a Drug Development Research Grant

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy and Research Centre

Psyched Wellness Announces July 19th, 2022 as the Official Date To Commence Pre-Orders for Calm

Red Light Holland to Head Sponsor Psy-Fi Festival in The Netherlands from September 14-18, 2022, One Of The Largest Psy-Trance Festivals In Europe

Telescope Inks Research Agreement With Standard Lithium

Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Filament Health Issued Third Patent by United States Patent and Trademark Office

Filament Health Announces Closing if $2,500,080 Private Placement

Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

Albert Labs Appoints Two Industry Leading Director

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Pure Extracts Provides Q3 Corporate Update

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Filament Health Announces First Dosing In Groundbreaking FDA-approved Psilocin Clinical Trial

The Trip of a Lifetime

Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds

Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Doseology Uplists to OTCQB Market in USA

Filament Health Announces Sixth Patent Issuance

IntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on Debentures

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Awakn Receives UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder

PharmAla Biotech appoints Kevin Roy to its Board of Directors

Lexston closes previously announced Non-Brokered Unit Private Placement

Algernon Pharmaceuticals Announces Closing of Public Offering of Units

An athlete’s take on microdosing

US military to study psychedelic therapy?

MAPS Raises Nearly $1.6 Million in Christie’s NFT Auction

MindMed Announces Completion of Share Redesignation

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Heads of Agreement secured with leading pharma and healthcare products company, China Chemical & Pharmaceutical Co., Ltd. (“CCPC”) to launch Sierra Sage Herbs LLC (“SSH”) products for Taiwanese animal healthcare market

Ketamine Wellness Centers (KWC) Launches Ketamine Wellness Integrative Therapist Directory

Filament Health Announces Private Placement Of Units And Convertible Debenture Units Of Up To $2,500,000

Pure Extracts Signs Listing Agreement With Shoppers Drug Mart and Receives Initial Purchase Order

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Psyched Wellness announces date for their pilot production run of the first legal Amanita Muscaria tincture product, Calm

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations

LOVE Pharma Inc. Announces Second Closing Of Financing

Optimi CEO, Bill Ciprick, Sits Down With Investing News Network (INN)

Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into Two Publicly Traded Companies

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Pure Extracts Receives Purchase Order for a New Listing of High-potency Vape Carts From the Ontario Cannabis Store

Red Light Holland Update Plans to Enter Oregon Legal Psilocybin Service Market to Promote Diversity and Equity in Alignment with Measure 109 Regulations

Incannex – Director and management update

HAVN Life Enters Supply Agreement With MPB Group Inc.

Optimi Health Initiates Agreement With Sabi Mind for Therapeutic Supplies of Psilocybin, MDMA

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

Filament Health Announces Annual General Meeting Voting Results

Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial

PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders

Telescope Launches First Automation Product

Prof. Dr. Raimar Loebenberg receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration

Greenbrook TMS Provides an Update on the Success TMS Acquisition

Lexston increases previously announced Non-Brokered Unit Private Placement

Numinus Unveils New Logo and Brand Identity

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

Cybin Announces Additional Adelia Milestone Achievement

FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders and Other Corporate Updates

Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

Oregon county opposing psilocybin measure

Colorado to vote on psilocybin measure this Fall!

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

PharmAla Biotech Registers Trademark for MDMA

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Silo Pharma Expands License Agreement and Patent Portfolio

Tryp Therapeutics Appoints New Chief Operating Officer

Ketamine for corporate wellness

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

BetterLife To Participate at the H.C. Wainwright 1st Annual
Mental Health Conference

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

HAVN Life to Be Featured on Viewpoint With Dennis Quaid

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

MAVIRET® (glecaprevir/pibrentasvir) Approved by Health Canada for Pediatric Patients with Chronic Hepatitis C

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Nova Mentis to Present at the H.C. Wainwright Mental Health Conference

Numinus Applies for International Patent Filing of Psychedelics Production Process

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

Volunteer at Burning Man

What machine learning tells us about microdosing

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program

Wellbeing Digital Sciences Announces the Appointment of Natalie Dolphin as VP of Marketing and Investment Relations

Awakn Life Sciences to Present In Upcoming June 2022 Conferences

MAPS under fire for alleged investigator misconduct

Optimi Health Requests Approval to Manufacture MDMA, Other Synthetic Psychedelics

Red Light Holland Closes Acquisition of 100 Acres of Farmland in Ontario, Canada Expanding its Mushroom Farms Division in North America

Stephen Bardin to Join atai Life Sciences as CFO Designate

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

atai Life Sciences to Participate in Upcoming June Healthcare Conferences

Blackhawk’s Terp Wholesale LLC Reports Unaudited CDN$1,644,043 in Gross Revenue for First Five Months Ended May 31st, 2022

Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

Delic Labs to Present on Psychedelics, Cannabis Extraction at Grow Up Conference and Expo

Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive) Supplementation in treating OA

How to Change Your Mind comes to Netflix!

Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives

PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study

Mike O’Shaughnessy Joins CaamTech as General Counsel and Director of Intellectual Property

Clearmind Medicine Appoints New Chief Financial Officer

Are functional mushrooms superior to psychedelic mushrooms?

Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022

HAVN Life Announces Changes to the Board of Directors

Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes

Psyched Wellness Announces the Official Launch of Their New eCommerce Online Store

Wtf is wood lovers paralysis?

Creso Pharma’s wholly-owned Canadian subsidiary, Mernova Medicinal Inc. receives maiden order for new strains, increases cannabis yields and gains acclaim at national cannabis competition

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022

Numinus completes acquisition of Novamind and announces executive appointments

Novamind Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Completes Acquisition by Numinus Wellness Inc.

Children took ayahuasca in ancient Incan ritual

AIkido Pharma Inc. Appoints New Director, Soo Yu

Filament Health Cultivates 70th Psychedelic Mushroom Variety And Announces Annual General Meeting

Psych Capital PLC Admission to AQSE

Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies

1 psilocybin therapy session = 12 months of therapy alone

Cybin receives two ‘Buy’ ratings

Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay

Mydecine Provides Company Update; Welcomes New Board Member

Lexston’s Subsidiaries Lay off Staff

Wellbeing subsidiary KGK Science and the International Probiotics Association (“IPA”) applauds FDA’s Commitment to Release NDI Draft Guidance Documents in the Near Future

Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Developing psychedelic treatments for ADHD and social anxiety

Enveric Biosciences to Participate in Upcoming Conferences in June 2022

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

XPhyto adds pharmaceutical manufacturing expert Dr. Florian A. Sahr to its European team

First Patient Dosed in Second Phase 2 Add-on Ketamine Trial in Treatment-resistant Depression (TRD)

One year of psychedelic news

Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind

Novamind Shareholders Approve Proposed Acquisition by Numinus

LOVE Pharma Inc. Announces First Closing of Financing

Nova Mentis Receives Controlled Substances Export Approval From The U.S DEA For The Company’s Proprietary Psilocybin Drug NM 1001

PharmaTher Announces Positive Results from Study of KETABET™ for Depression

Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Lobe Sciences Announces Share Consolidation

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Stability Test Under a Health Canada Approved cGMP Laboratory

Blackhawk Appoints Justin Hanka as Chairman of The Board

Women-focused psilocybin study for depression

Lexston Announces cancellation of Stock Options

AIkido Announces Reverse Stock Split

Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea

Cybin Announces Additional Adelia Milestone Achievements

Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022

PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia

Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

Novamind Announces New Patient Financing Options

Psyence Group Corporate Update

Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Cybin to Host Key Opinion Leader Webinar on June 9, 2022

Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

CaaMTech Collaboration Proves Diversity in Magic Mushroom Chemistry

Largest psychedelic neuroimaging study to date

Wellbeing Digital Sciences’ Dr. Corey Hilmas Invited to Participate as a Regulatory Panelist at Probiota Americas Event

Lexston Announces Non-Brokered Unit Private Placement

Mindmed Announces Voting Results for Annual General and Special Meeting

Greenbrook TMS to Host Investor Webcast on June 7, 2022

Cannabis Global Comments on Its Dramatic Business Turnaround – While Many Cannabis Companies Are Retrenching, CBGL Exceeds in Most Categories

Ketamine Wellness Centers (KWC) Launches SPRAVATO® Nasal Spray Therapy in Minneapolis, Salt Lake City and Dallas

Doseology Opens to American Investors

Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

IntelGenx Announces Intention to Issue Shares in Payment of Principal and Interest on Outstanding Debentures

MindMed to Participate in the Jefferies Global Healthcare Conference

Clearmind Medicine Granted Patent Approval for Psychedelic-Based Alcohol Substitute in India

Why ketamine reduces depression so quickly

BC becomes first province to decriminalize illicit drugs

Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin